Sign in

CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
823562771
Phone
(650) 457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 5 Insider Annual Insider Trading Report
  2. 4 Open-market sale Chief Financial Officer sold 30,000 shares at an average $31.52 ($945,469)
  3. 4 Option exercise General Counsel acquired 51,500 shares (option exercise)
  4. 8-K Event Material agreement
  5. 8-K Event Other events
  6. 4 Open-market sale Chief Financial Officer sold 15,000 shares at an average $32.88 ($493,146)
  7. 10-Q Report Quarterly Report
  8. 8-K Event Results of operations
  9. 8-K/A Event Shareholder vote results
  10. 4 Open-market sale Chief Financial Officer sold 15,000 shares at an average $40.49 ($607,392)
  11. 4 Open-market sale Chief Technical Officer sold 35,264 shares at $42.00 ($1,481,088)
  12. 4 Open-market sale Chief Technical Officer sold 44,574 shares at $41.00 ($1,827,534)
  13. 4 Open-market sale EVP of R&D and CMO sold 16,538 shares at $39.40 ($651,515)
  14. 4 Open-market sale Chief Technical Officer sold 44,574 shares at $40.00 ($1,782,960)
  15. 4 Open-market sale General Counsel sold 10,000 shares at $40.00 ($400,000)
  16. 4 Open-market sale General Counsel sold 25,000 shares at an average $36.52 ($912,913)
  17. 4 Open-market sale EVP of R&D and CMO sold 9,752 shares at $36.37 ($354,662)
  18. 4 Open-market sale Chief Financial Officer sold 15,000 shares at an average $35.30 ($529,545)
  19. 4 Open-market sale General Counsel sold 25,000 shares at an average $35.36 ($883,966)
  20. 4 Option exercise Chief Technical Officer acquired 32,451 shares (option exercise)

Page 22 of 30 · 587 filings